Completed

Improving Blood Safety and HIV Testing in Brazil: a Randomized Controlled Trial

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

HIV Counseling and Testing

+ Blood Donation

+ HIV Counseling and Testing

Behavioral
Who is being recruted

Vector Borne Diseases+17

+ Blood-Borne Infections

+ Communicable Diseases

From 18 to 65 Years
See all eligibility criteria
How is the trial designed

Prevention Study

Interventional
Study Start: August 2012
See protocol details

Summary

Principal SponsorVitalant Research Institute
Last updated: January 18, 2018
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2012

Actual date on which the first participant was enrolled.

Although all donated blood is screened for HIV antibodies, a residual risk of contamination persists due to the immunological window period before antibodies are detectable. Deferral of donors with behavioral risks for HIV is one means to reduce window period contamination; recruitment of voluntary donors from the community (versus family replacement donors) is held to be another. Contrary to expectation, a shift to community donors has not resulted in a decrease in HIV prevalence in units of blood collected by the investigators transfusion service. The investigators preliminary research indicates that some persons at elevated risk use donation as a means of testing for HIV. These test-seeking donors have high trust in the blood bank, do not know other places to receive testing, have low understanding of the immunological window period and believe it is acceptable to deny risk in order to be tested through donation. The test-seeking phenomenon may therefore threaten the safety of the blood supply. Test seeking at blood banks also ill serves persons who need risk reduction counseling because they cannot disclose their true behavior during the donation process and still be tested. Donors also have a low rate of return for test results and therefore do not receive confirmation or referrals to care. To assess whether HCT at the time of donation will improve blood safety and address prevention and care needs, the investigators will randomize donor candidates to be offered this service on-site. As a biological marker for elevated risk for HIV, the investigators will compare the prevalence of HSV-2 among donors choosing testing to those choosing to donate when offered the choice (Aim 1). The impact of the intervention will be measured as an increase in persons receiving their test results, disclosure counseling and referrals (Aim 2). Secondary outcomes include differences in prevalence of transfusion-transmitted infections (HIV, HCV, HBV, syphilis, HTLV I/II, Chagas disease), donor motivations (e.g., test-seeking vs. altruism), donor deferral rates, use of confidential unit exclusion, satisfaction with procedures of the blood bank and volume of blood available for use. RCT results will provide rigorous evidence for or against the provision of on-site HCT as an effective means to improve blood safety and link individuals to needed health services.

Principal SponsorVitalant Research Institute
Last updated: January 18, 2018
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

11900 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Vector Borne DiseasesBlood-Borne InfectionsCommunicable DiseasesDigestive System DiseasesDNA Virus InfectionsHepatitisHepatitis, Viral, HumanInfectionsLiver DiseasesParasitic DiseasesProtozoan InfectionsRNA Virus InfectionsTrypanosomiasisVirus DiseasesFlaviviridae InfectionsHepadnaviridae InfectionsEuglenozoa InfectionsHepatitis BHepatitis CChagas Disease

Criteria

Inclusion Criteria: Study subjects will be Portuguese-speaking persons age 18-65 years (determined by Brazilian law to be the age of donation), who present to donate blood at our center during the study period and who provide written informed consent. Exclusion Criteria: All those not meeting inclusion criteria.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.

Group II

Experimental
Approved blood donors randomized to intervention and choosing donation with no HIV counseling.

Group III

Experimental
Deferred blood donors randomized to intervention with HIV counseling.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Fundação Pró-sangue Hemocentro de São Paulo

São Paulo, BrazilOpen Fundação Pró-sangue Hemocentro de São Paulo in Google Maps
CompletedOne Study Center